You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR RAPAFLO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rapaflo

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00224107 ↗	A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo	Completed	Watson Pharmaceuticals	Phase 3	2005-05-01	A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224120 ↗	A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo	Completed	Watson Pharmaceuticals	Phase 3	2005-05-01	A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224133 ↗	The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months	Completed	Watson Pharmaceuticals	Phase 3	2005-09-01	A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
NCT00740779 ↗	Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.	Completed	Watson Pharmaceuticals	Phase 2	2008-09-01	The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Rapaflo

Condition Name

Chart
Table

Condition Name for Rapaflo
Intervention	Trials
Benign Prostatic Hyperplasia	2
Ureterolithiasis	1
Urinary Problems	1
Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Rapaflo
Intervention	Trials
Prostatic Hyperplasia	4
Hyperplasia	4
Chronic Disease	1
Prostatic Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Rapaflo

Trials by Country

Map
Table

Trials by Country for Rapaflo
Location	Trials
United States	116
Canada	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Rapaflo
Location	Trials
Washington	5
Pennsylvania	5
New York	5
California	5
Maryland	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Rapaflo

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Rapaflo
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	4
Phase 2	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Rapaflo
Clinical Trial Phase	Trials
Completed	5
Recruiting	1
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rapaflo

Sponsor Name

Chart
Table

Sponsor Name for Rapaflo
Sponsor	Trials
Watson Pharmaceuticals	5
Sir Mortimer B. Davis - Jewish General Hospital	1
Albert Einstein Healthcare Network	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Rapaflo
Sponsor	Trials
Industry	5
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.